{"groups":[{"description":"Radiation therapy with concurrent trastuzumab, paclitaxel, and carboplatin followed by surgery followed by maintenance trastuzumab","id":"FG000","title":"Chemoradiation and Trastuzumab"},{"description":"Radiation therapy with concurrent paclitaxel and carboplatin followed by surgery","id":"FG001","title":"Chemoradiation"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"5"}],"type":"Protocol Violation"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"102"},{"groupId":"FG001","numSubjects":"101"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"98"},{"groupId":"FG001","numSubjects":"96"}],"type":"Eligible"},{"achievements":[{"groupId":"FG000","numSubjects":"95"},{"groupId":"FG001","numSubjects":"96"}],"type":"Eligible and Started Study Treatment"},{"achievements":[{"groupId":"FG000","numSubjects":"82"},{"groupId":"FG001","numSubjects":"78"}],"type":"Eligible and Had Surgery"},{"achievements":[{"groupId":"FG000","numSubjects":"88"},{"groupId":"FG001","numSubjects":"83"}],"type":"Eligible and Consented to Quality of Life Component"},{"achievements":[{"groupId":"FG000","numSubjects":"98"},{"groupId":"FG001","numSubjects":"96"}],"comment":"Participants contributing data to results are considered to have completed the study","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"5"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"After registration, sites were required to submit participant tumor tissue for central human epidermal growth factor receptor 2 (HER2) testing. Only HER2-positive participants continued to randomization. In total, 571 participants were registered and 203 were randomized."}